Stockreport

Stemline Therapeutics Announces Completion of Rolling BLA Submission for ELZONRIS™ (tagraxofusp; SL-401) for the Treatment of BPDCN

STEMLINE THERAPEUTICS  (STML) 
Last stemline therapeutics earnings: 3/13 04:45 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.stemline.com/investor-relations
PDF NEW YORK, June 25, 2018 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel oncology therapeutic [Read more]